Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 3, 2008

Dr. Reddy’s Makes Its Second Acquisition This Week

  • Dr. Reddy's acquired Jet Generici, a company engaged in the sale of generic finished dosages in Italy. The deal was completed by Reddy Pharma Italia, Dr. Reddy’s subsidiary. 

    This represents Dr. Reddy's second one this week; on April 1, a part of Dow Pharma's small molecule business was bought. Jet Generici will provide access to an essential product portfolio, a pipeline of registration applications, and a sales and marketing organization.

    “Dr. Reddy's has taken a significant step forward by establishing its business in the third largest pharmaceutical market in Europe,” note VS Vasudevan, president and head of European operations for Dr. Reddy’s. "The acquisition has been well timed, since Dr. Reddy's will be able to immediately supplement the Jet Generici portfolio via its own pipeline. We already have registration for one significant Dr. Reddy's product, and a strong pipeline of registration applications."



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »